SEC For	m 4																			
FORM 4 UN				UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549														OMB APPROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					led pu	irsuant	to Section	n 16(a	a) of the Sec	uritie	es Exchan		HIP	Estim	Numbe nated av s per res	erage burde	3235-0287 n 0.5			
1. Name and Address of Reporting Person [*] <u>Yoon Jun</u>						2. Issuer Name and Ticker or Trading Symbol <u>Structure Therapeutics Inc.</u> [GPCR]									elationship o ck all applic Director Z Officer	able)	ng Pers	on(s) to Iss 10% Ov Other (s	ner	
(Last)(First)(Middle)C/O STRUCTURE THERAPEUTICS INC.611 GATEWAY BLVD., SUITE 223						3. Date of Earliest Transaction (Month/Day/Year) 02/02/2023									X Onicer (give nue Onier (specify below) below) Chief Financial Officer					
(Street) SOUTH FRANC	· · · · · · · · · · · · · · · · · · ·	94080			If Ame	of Original Fi	Original Filed (Month/Day/Year)				Line) 🏹 Form fi	led by On led by Mo	t/Group Filing (Check Applic by One Reporting Person by More than One Reportir		n				
(City) (State) (Zip)																				
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transi Date (Month/L)					sactio	on Year)	2A. Deemed Execution Date, if any (Month/Day/Year		3. Transaction Code (Instr.		4. Securities Acquired (A)		(A) or	5. Amoun Securities Beneficia Owned Fe	s Ily ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code \	/	Amount	(A) (D)		Price	Reported Transacti (Instr. 3 a	on(s)			(Instr. 4)	
			Table II -						uired, Dis s, options						Owned			· · · · ·		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration I (Month/Day		7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivativ Securitie Beneficia Owned Followin Reported Transact	e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)		Date Exercisable		xpiration ate	Title	or Ni	mount r umber f Shares		(Instr. 4)				
Stock option (right to buy)	\$15	02/02/2023			Α		750,000		(1)	02	2/01/2033	Ordinary Shares	y 7:	50,000	\$0.00	750,0	000	D		

Explanation of Responses:

1. 1/4th of the shares subject to the option shall vest on the first anniversary of February 2, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Remarks:

/s/ Jun Yoon

02/03/2023 Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.